Longevity Acquisition Corporation (LOAC)

Etorro trading 970x250

About Longevity Acquisition Corporation

Longevity Acquisition Corporation does not have significant operations. The company focuses on acquiring, engaging in a share exchange, share reconstruction and amalgamation, purchasing of assets, entering into contractual arrangements, or other business combination with one or more businesses. Longevity Acquisition Corporation was founded in 2018 and is based in Shanghai, the People’s Republic of China. Address: Yongda International Tower No. 2277, Shanghai, China

Longevity Acquisition Corporation News and around…

Latest news about Longevity Acquisition Corporation (LOAC) common stock and company :

4D pharma Announces Completion of Merger With Longevity Acquisition Corporation
22 Mar, 2021 FinancialContent

4D pharma plc (Nasdaq: LBPS; AIM: DDDD) ("4D pharma" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome - today announced completion of its merger (“the Merger”) with Longevity Acquisition Corporation ("Longevity")(Nasdaq: LOAC).

4D Pharma Announces Private Placement
17 Mar, 2021 FinancialContent

4D pharma plc (AIM: DDDD) ("4D" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces it has entered into Securities Purchase Agreements with a select group of U.S. and United Kingdom institutional investors and accredited investors to raise, in aggregate, approximately $24.03 million (£17.29 million) in a private placement (the "Fundraising") of new ordinary shares of £0.0025 each (the "Placing Shares") at $1.53 (£1.10) per share (the "Issue Price"). In addition, Duncan Peyton (Chief Executive Officer) and Alex Stevenson (Chief Scientific Officer) intend to subscribe for, in aggregate, $2.0 million (£1.44 million) once the Company has released the results for the year ended 31 December 2020, expected to be on or around 25 March 2021.

4D Pharma to Present at Upcoming Investor Conferences in March
03 Mar, 2021 FinancialContent

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announced that 4D management will present at three upcoming investor conferences:

4D Pharma Appoints John Beck as Chief Financial Officer and Member of the Management Team
01 Mar, 2021 FinancialContent

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of John Beck as Chief Financial Officer (CFO) and member of the Company’s management team, bringing over 30 years of experience in finance, including three previous positions as Chief Financial Officer of publicly traded life sciences companies.

4D Pharma Announces U.S. SEC Declares Registration Statement Effective with Respect to the Issuance of 4D Pharma American Depositary Shares on NASDAQ
26 Feb, 2021 FinancialContent

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces that the United States Securities and Exchange Commission (“SEC”) has declared effective its registration statements on Form F-4 with respect to the issuance of 4D pharma American Depositary Shares (“ADSs”) to the shareholders of Longevity Acquisition Corporation (NASDAQ: LOAC) (“Longevity”), a NASDAQ-listed special purpose acquisition company (“SPAC”), in connection with the previously announced merger between 4D pharma and Longevity.

4D pharma Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with BAVENCIO® for the Treatment of Locally Adva
08 Feb, 2021 FinancialContent

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. for BAVENCIO® (avelumab), the first and only immunotherapy approved as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma. BAVENCIO is co-developed and co-commercialized by Merck KGaA, Darmstadt, Germany and Pfizer Inc.

4D Pharma Presents Update on Oncology Program
03 Feb, 2021 FinancialContent

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces progress on activities in its development program for lead immuno-oncology single strain Live Biotherapeutic candidate MRx0518.

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of SNSS, LOAC, FBSS, and CPAH Mergers
07 Jan, 2021 FinancialContent
84 Biggest Movers From Yesterday
29 Dec, 2020 FinancialContent

Gainers AeroCentury Corp. (NYSE: ACY) shares climbed 414.9% to close at $13.85 on Monday after the company reported that the NYSE ...

Stocks That Hit 52-Week Highs On Monday
28 Dec, 2020 FinancialContent

This morning 301 companies reached new 52-week highs. Significant Points: The largest company by market cap to break ...

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of ELY, LOAC, ROCH, and NGA Mergers
17 Dec, 2020 FinancialContent
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Longevity Acquisition Corporation Merger
02 Dec, 2020 FinancialContent
4D pharma plc Files SEC Forms in Process to Gain NASDAQ Listing Following Merger with Longevity, a Special Purpose Acquisition Company (SPAC)
27 Nov, 2020 FinancialContent

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the filing of a registration statement on Form F-4 (the “Registration Statement”) with the US Securities and Exchange Commission (SEC). The filing follows the announcement on October 22, 2020 of the proposed merger between 4D pharma and Longevity Acquisition Corporation (NASDAQ: LOAC) ("Longevity"), a NASDAQ-listed Special Purpose Acquisition Company (“SPAC”).

Stocks That Hit 52-Week Highs On Friday
20 Nov, 2020 FinancialContent

During Friday's morning session, 91 stocks hit new 52-week highs. Noteworthy Highlights: The largest company on a ...

Stocks That Hit 52-Week Highs On Wednesday
18 Nov, 2020 FinancialContent

Before 10 a.m. ET on Wednesday, 185 stocks hit new 52-week highs. Intriguing Points: Comcast (NASDAQ: CMCSA) was the ...

4D Pharma Presents New Data from Two MRx0518 Clinical Trials at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
09 Nov, 2020 FinancialContent

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces new positive clinical data from two clinical trials of MRx0518, its lead immuno-oncology single strain Live Biotherapeutic candidate. The data is presented in three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020, November 9-14, 2020.

4D Pharma to Host Virtual KOL Event Reviewing New Data Presented at the Society for Immunotherapy of Cancer Annual Meeting 2020 from Live Biotherapeutic MRx0518 Clinical Programs
05 Nov, 2020 FinancialContent

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces that it will host a virtual Key Opinion Leader (KOL) event to review data presented from two ongoing clinical trials of MRx0518, the Company’s lead immuno-oncology single strain Live Biotherapeutic, as both a neoadjuvant monotherapy and combination therapy in patients refractory to checkpoint inhibitors at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020. The event will take place on Wednesday, November 11, 2020 at 1:00pm GMT (8:00am ET).

Longevity Acquisition Corporation (LOAC) is a NASDAQ Common Stock listed in , ,

970x250